Tasigna 200 mg 28 hard gelatin caps

Tasigna 200 mg 28 hard gelatin caps

5700.00 جنيها

معلومات الدواء

الإسم التجاري

Tasigna 200 mg 28 hard gelatin caps -

الإسم العلمي 

Nilotinib

الشركات المنتجة

Novartis,
Indication for the potential treatment of various leukemias, including chronic myeloid leukemia (cml).pharmacodynamics nilotinib is a transduction inhibitor that targets bcr-abl, c-kit and pdgf, for the potential treatment of various leukemias, including chronic myeloid leukemia (cml).mechanism of action chronic myelogenous leukaemia (cml) is caused by the bcr-abl oncogene. nilotinib inhibits the tyrosine kinase activity of the bcr-abl protein. nilotinib fits into the atp-binding site of the bcr-abl protein with higher affinity than imatinib, over-riding resistance caused by mutations. the ability of amn107 to inhibit tel-platelet-derived growth factor receptor-beta (tel-pdgfrbeta), which causes chronic myelomonocytic leukaemia, and fip1-like-1-pdgfralpha, which causes hypereosinophilic syndrome, suggests potential use of amn107 for myeloproliferative diseases characterised by these kinase fusions (stover et al, 2005- weisberg et al, 2005). amn107 also inhibits the c-kit receptor k
Indication for the potential treatment of various leukemias, including chronic myeloid leukemia (cml).pharmacodynamics nilotinib is a transduction inhibitor that targets bcr-abl, c-kit and pdgf, for the potential treatment of various leukemias, including chronic myeloid leukemia (cml).mechanism of action chronic myelogenous leukaemia (cml) is caused by the bcr-abl oncogene. nilotinib inhibits the tyrosine kinase activity of the bcr-abl protein. nilotinib fits into the atp-binding site of the bcr-abl protein with higher affinity than imatinib, over-riding resistance caused by mutations. the ability of amn107 to inhibit tel-platelet-derived growth factor receptor-beta (tel-pdgfrbeta), which causes chronic myelomonocytic leukaemia, and fip1-like-1-pdgfralpha, which causes hypereosinophilic syndrome, suggests potential use of amn107 for myeloproliferative diseases characterised by these kinase fusions (stover et al, 2005- weisberg et al, 2005). amn107 also inhibits the c-kit receptor k

تنبيه بخصوص المعلومات المتوفرة علي موقع دليل الدواء

بينما نعمل دائما علي تنقيح وتحسين البيانات المعروضة علي موقعنا إلا أننا ننصح دائما بعدم تعاطي أي دواء بدون إستشارة الطبيب المختص، ولا يتحمل الموقع أي مسئولية ناتجة عن سوء استخدام الأدوية بدون استشارة المختص، في حال وجدت أي بيانات خاطئة أو سعر دواء غير صحيح برجاء الإتصال بنا لتصحيحه.
الإبلاغ عن مشكلة

البدائل

0 دواء

لا يوجد بدائل مسجلة لدينا لهذا الدواء